Endovascular treatment using N-Butyl Cyanoacrylate (NBCA) liquid adhesive for arteriovenous malformations, dural arteriovenous fistulas and brain tumors

Endovascular treatment using N-Butyl Cyanoacrylate (NBCA) liquid adhesive for arteriovenous malformations, dural arteriovenous fistulas and brain tumors - Endovascular treatment using NBCA for arteriovenous malformations, dural arteriovenous fistulas and brain tumors

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000020435

Enrollment

Registered

2016-01-05

Start date

2015-06-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

arteriovenous malformations, dural arteriovenous fistulas and brain tumors

Interventions

treatment using NBCA The dosage period: during the endovascular treatment The dosage:0.1ml-0.5ml NBCA per feeding artery The dosage number of times: 1-5 feeding arteries

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. large size arteriovenous malformations could not operated simply or radiosurgery simply 2. dural arteriovenous malformations could not reached by transvenous approach 3. large brain tumors that have vascular feeders

Exclusion criteria

Exclusion criteria: the cases whose feeding arteries could not reached by micro catheters

Design outcomes

Primary

Measure	Time frame
Evaluation for the endovascular treatment using NBCA for the feeding arteries The treatment next day: MRI	—

Secondary

Measure	Time frame
Occurrence of the treatment complication and adverse event	—

Countries

Japan

Contacts

Public ContactMohri Masanao

Graduate School of Medical Science Kanazawa university Department of Neurosurgery

mmohri@med.kanazawa-u.ac.jp076-265-2384

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026